Rule logic

GPES At Risk v4

RTDS within the last 6 months

HES (2006+)

GPES At Risk v4

Allogeneic haematopoietic stem cell transplant (HSCT) recipients in the last 12 months or active graft vs host disease (GVHD) regardless of time from transplant.

Autologous HSCT recipients in the last 12 months.

GPES At Risk v4

As per Shielded Patient List rules.

All HSCT transplants are currently included for clinical triage regardless of time from transplant.

Individuals with haematological malignancies who have:

• received systemic anti-cancer treatment (SACT) within the last 12 months except patients with chronic phase chronic myeloid leukaemia (CML) in molecular response or first or second line tyrosine kinase inhibitors (TKI)
• received chimaeric antigen receptor (CAR)-T cell therapy in the last 24 months, or 
• anti-CD20 monoclonal antibody therapy in the last 12 months 
• received anti-CD38 monoclonal antibody or B-cell maturation agent (BCMA) targeted therapy in the last 6 months 

GPES At Risk v4

GDPPR

All haematological malignancies are included where they are receiving systemic anti-cancer treatment (SACT) within the last 12 months.

There is also digital cohorting limitation that hospital only medication is not stored centrally. A non-digital solution will cover all patients receiving hospital only medication via the haematology units (see section below).

GPES At Risk v4

Population Risk Assessment (PRA) code clusters.

All myeloma, chronic B-cell lymphoproliferative and myelodysplastic syndrome (MDS) disorders are currently included for clinical triage.

Renal transplant recipients (including those with failed transplants within the past 12 months), particularly those who:

• received B cell depleting therapy within the past 12 months (including alemtuzumab, rituximab [anti-CD20], anti-thymocyte globulin)
• have an additional substantial risk factor which would in isolation make them eligible for nMABs or oral antivirals
• not been vaccinated prior to transplantation 

GPRSv4

HES (2006+)

As per Shielded Patient List rules. Includes all solid transplant patients for clinical triage, regardless of treatment, risk factors and vaccination status, excluding the SPL rule that restricted identification of patients to those with PCPM immunosuppression medication.

Excludes autologous transplants 

Population Risk Assessment (PRA) code clusters for Immunosuppressant drugs. Anyone, regardless of clinical condition, who has had one of these drugs issued within the last 6 months.

There is a digital cohorting limitation that hospital only medication is not stored centrally, therefore there is a non-digital solution for any patients who have had immunosuppressant drugs within the last 6 months that are only hospital prescribed (see section below).

GPESv4

GPESv4

Patients with cirrhosis Child’s-Pugh class B and C (decompensated liver disease).

Patients with cirrhosis Child’s-Pugh class A who are not on immune suppressive therapy (compensated liver disease).

GPESv4

HES (2006+)

GPESv4

HES (2006+)

As per Shielded Patient List rules. Includes all solid transplant patients for clinical triage, excluding the SPL rule that restricted identification of patients to those with PCPM immunosuppression medication.

Excludes autologous transplants.

Population Risk Assessment (PRA) code clusters for Immunosuppressant drugs. Anyone, regardless of clinical condition, who has had one of these drugs issued within the last 6 months.

There is a digital cohorting limitation that hospital only medication is not stored centrally, therefore there is a non-digital solution for any patients who have had immunosuppressant drugs within the last 6 months that are only hospital prescribed (see section below).

IMID treated with rituximab or other B cell depleting therapy in the last 12 months.

IMID with active/unstable disease on corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate.

IMID with stable disease on either tacrolimus, cyclophosphamide, cyclosporin or mycophenolate.

IMID patients with active/unstable disease including those on biological monotherapy and on combination biologicals with thiopurine or methotrexate.

IMID with stable disease on either tacrolimus, cyclophosphamide, cyclosporin or mycophenolate.

IMID patients with active/unstable disease including those on biological monotherapy and on combination biologicals with thiopurine or methotrexate.

GPES At Risk v4

GDPPR

Population Risk Assessment (PRA) code clusters for Immunosuppressant drugs. Anyone, regardless of clinical condition, who has had one of these drugs issued within the last 6 months.

There is a digital cohorting limitation that hospital only medication is not stored centrally, therefore there is a non-digital solution for any patients who have had immunosuppressant drugs within the last 6 months that are only hospital prescribed (see section below).

IMID with active/unstable disease on corticosteroids.

IMID with stable disease on corticosteroids.

All patients on corticosteroids (where 2 prescriptions have been issued in 3 month, or 4 prescriptions in 12 months) are included in the for clinical triage.

Common variable immunodeficiency (CVID).

Undefined primary antibody deficiency on immunoglobulin (or eligible for Ig).

Hyper-IgM syndromes.

Good’s syndrome (thymoma plus B-cell deficiency).

Severe Combined Immunodeficiency (SCID).

Autoimmune polyglandular syndromes/autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome).

Primary immunodeficiency associated with impaired type I interferon signalling.

X-linked agammaglobulinaemia (and other primary agammaglobulinaemias).

GPES At Risk v4

Population Risk Assessment (PRA) code clusters.

There is a digital cohorting limitation in that Autoimmune polyglandular syndromes/autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome) is not included. A non-digital solution will cover the deficit via the specialist units (see section below).

Patients with high levels of immune suppression, have uncontrolled/untreated HIV (high viral load) or present acutely with an AIDS defining diagnosis.

On treatment for HIV with CD4 350 cells/mm3 and additional risk factors (for example age, diabetes, obesity, cardiovascular, liver or renal disease, homeless, those with alcohol-dependence).

GPESv4

GDPPR

Population Risk Assessment (PRA) code clusters.

Includes all people with HIV regardless of CD4 count, viral load and risk factors. 

All recipients of solid organ transplants not otherwise specified above.

GPRSv4

HES (2006+)

OPCS4

Clinically Extremely Vulnerable codes that were identified for SPL implementation.

Multiple sclerosis

Motor neurone disease

Myasthenia gravis

Huntington’s disease

GPESv4

HES (2006+)

Population Risk Assessment (PRA) code clusters.

collated by the nMABS clinicians to restrict the data to the 4 disease groups.